BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3217992)

  • 1. Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial.
    Tomirotti M; Perrone S; Giè P; Canaletti R; Carpi A; Biasoli R; Lombardi F; Giovanninetti A; Mensi F; Villa S
    Tumori; 1988 Oct; 74(5):573-7. PubMed ID: 3217992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of the combination of cisplatin, adriamycin and cyclophosphamide in the treatment of ovarian carcinoma.
    Russo A; Gebbia V; Palmeri S; Geraci P; Maneschi F; Guarnieri G; Carollo F; Leonardi V; Meli M; Gebbia N
    Eur J Gynaecol Oncol; 1993; 14(3):228-33. PubMed ID: 8508880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
    Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
    Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
    Omura G; Blessing JA; Ehrlich CE; Miller A; Yordan E; Creasman WT; Homesley HD
    Cancer; 1986 May; 57(9):1725-30. PubMed ID: 3513943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
    Omura GA; Bundy BN; Berek JS; Curry S; Delgado G; Mortel R
    J Clin Oncol; 1989 Apr; 7(4):457-65. PubMed ID: 2926470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Tsukada Y; Emrich LJ
    J Clin Oncol; 1988 Jun; 6(6):983-9. PubMed ID: 3373267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies.
    Belinson JL; Pretorius RG; McClure M; Ashikaga T
    Gynecol Oncol; 1986 Mar; 23(3):304-9. PubMed ID: 3082726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Eur J Gynaecol Oncol; 1998; 19(1):5-10. PubMed ID: 9476049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center.
    Wils JA
    Oncology; 1990; 47(2):115-20. PubMed ID: 2107480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
    Bertelsen K; Jakobsen A; Strøyer J; Nielsen K; Sandberg E; Andersen JE; Ahrons S; Nyland M; Hjortkjaer Pedersen P; Larsen G
    Gynecol Oncol; 1993 Apr; 49(1):30-6. PubMed ID: 8482557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.
    Edmonson JH; McCormack GW; Fleming TR; Cullinan SA; Krook JE; Malkasian GD; Podratz KC; Mailliard JA; Jefferies JA; Barlow JF
    Cancer Treat Rep; 1985 Nov; 69(11):1243-8. PubMed ID: 3937598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study.
    Kolarić K; Vukas D; Potrebica V
    Tumori; 1989 Apr; 75(2):132-6. PubMed ID: 2741218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
    Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
    J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of cisplatin, vinblastine, and bleomycin versus cyclophosphamide, aclacinomycin, and cisplatin in epithelial ovarian cancer.
    Tokuhashi Y; Kikkawa F; Tamakoshi K; Suganuma N; Kuzuya K; Arii Y; Kawai M; Hattori S; Kobayashi I; Furuhashi Y; Nakashima N; Tomoda Y
    Oncology; 1997; 54(4):281-6. PubMed ID: 9216851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
    Hakes TB; Chalas E; Hoskins WJ; Jones WB; Markman M; Rubin SC; Chapman D; Almadrones L; Lewis JL
    Gynecol Oncol; 1992 Jun; 45(3):284-9. PubMed ID: 1612505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy.
    Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ
    Oncology; 1990; 47(2):109-11. PubMed ID: 2314822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide, adriamycin and cisplatin (CAP) versus cyclophosphamide, adriamycin and vincristin (CAV) in the treatment of advanced ovarian cancer: a randomized study.
    Krommer CF; Szalai JP
    Ann Oncol; 1992 Jan; 3(1):37-9. PubMed ID: 1606067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.